Advanced Filters
noise

idiopathic-membranous-nephropathy Clinical Trials

A listing of idiopathic-membranous-nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 24 clinical trials
S Sanxi Ai

Different Immunosuppressive Treatment in iMN

The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)

18 - 80 years of age Both Phase 3
S Sanxi Ai

Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).

18 - 80 years of age Both Phase 3

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases. During …

18 - 100 years of age Both Phase 1/2

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on …

18 - 75 years of age Both Phase 2/3

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Background Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and …

18 - 100 years of age Both Phase 2

Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy

This is a prospective, multicenter, randomized, open-label, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier granule on the treatment of idiopathic membranous nephropathy comparing with Ciclosporin soft capsules.

18 - 75 years of age Both Phase 4
Y Yosuke Saka, PhD, MD

Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome

To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.

15 - 100 years of age Both Phase 3
W Wenhu Liu, Doctor

the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy

This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the cognitive status of patients with Idiopathic membranous nephropathy, and explore the possible pathophysiological mechanism by using brain magnetic resonance …

18 - 70 years of age Both Phase N/A
P Piero Luigi Ruggenenti, MD

Obinutuzumab in Primary MN

Primary membranous nephropathy (MN) is an antibody-mediated autoimmune glomerular disease, that represents one of the most frequent causes of nephrotic syndrome in adults. The first-generation chimeric anti-CD20 monoclonal antibody rituximab is effective in inducing MN remission in the majority of patients, but a significant fraction of them can experience disease …

18 - 100 years of age Both Phase 2
N Nancy Kuntz, MD

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (ZL-1103-014)

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).

18 - 100 years of age Both Phase 2

Rewrite in simple language using AI